ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
Phase 3
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: Placebo ointment
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 226
- Registration Number
- NCT00480610
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2225
- Registration Number
- NCT00463541
A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation
Phase 3
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 42
- Registration Number
- NCT00459719
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 739
- Registration Number
- NCT00454896
Assessment and Tracking of Long-term Alefacept Safety
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1897
- Registration Number
- NCT00454701
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Georgia Skin Specialists, Atlanta, Georgia, United States
🇺🇸Advanced Dermatology, Fresh Meadows, New York, United States
Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 441
- Registration Number
- NCT00454740
A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 97
- Registration Number
- NCT00454233
- Locations
- 🇷🇺
4 Sites, Moscow, Russian Federation
🇷🇺10 Sites, St. Petersburg, Russian Federation
A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients
Phase 2
Completed
- Conditions
- Liver Transplantation
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2008-04-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 303
- Registration Number
- NCT00451932
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 448
- Registration Number
- NCT00448214
Zolpidem Postmarketing Study in Adolescent Patients With Insomnia
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 122
- Registration Number
- NCT00432198
© Copyright 2025. All Rights Reserved by MedPath